Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Net Cash Flow: 2014-2024

Historic Net Cash Flow for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to $136.0 million.

  • Cartesian Therapeutics' Net Cash Flow fell 112.83% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.8 million, marking a year-over-year decrease of 154.17%. This contributed to the annual value of $136.0 million for FY2024, which is 558.00% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Net Cash Flow stood at $136.0 million for FY2024, which was up 558.00% from -$29.7 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Net Cash Flow ranged from a high of $136.0 million in FY2024 and a low of -$29.7 million during FY2023.
  • Moreover, its 3-year median value for Net Cash Flow was -$7.4 million (2022), whereas its average is $33.0 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first plummeted by 300.34% in 2023, then skyrocketed by 558.00% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Net Cash Flow (Yearly) stood at $48.6 million in 2020, then crashed by 150.70% to -$24.6 million in 2021, then surged by 69.88% to -$7.4 million in 2022, then tumbled by 300.34% to -$29.7 million in 2023, then surged by 558.00% to $136.0 million in 2024.